Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dipyridamole -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; mannitol; colloidal anhydrous silica; magnesium stearate - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; maize starch; mannitol - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; maize starch; povidone; colloidal anhydrous silica - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram/ml (equivalent: ipratropium bromide, qty 500 microgram/ml) - inhalation, conventional - excipient ingredients: sodium chloride; hydrochloric acid; purified water - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 0.261 mg/ml (equivalent: ipratropium bromide, qty 0.25 mg/ml) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; sodium chloride; hydrochloric acid; disodium edetate - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 261 microgram/ml (equivalent: ipratropium bromide, qty 250 microgram/ml) - inhalation, conventional - excipient ingredients: purified water; sodium chloride; hydrochloric acid - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 10mg - injection with diluent - 10 mg - active: alteplase 10mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 20mg - injection with diluent - 20 mg - active: alteplase 20mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 50mg - injection with diluent - 50 mg - active: alteplase 50mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.